Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylenedioxymetamfetamine - MAPS Europe B.V.

Next Previous
Drug Profile

Methylenedioxymetamfetamine - MAPS Europe B.V.

Alternative Names: ecstasy; MDMA; Methylenedioxymetamphetamine; Methylenedioxymethamfetamine; Methylenedioxymethamphetamine; Midomafetamine

Latest Information Update: 09 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MAPS Europe B.V.
  • Developer Lykos Therapeutics; MAPS Europe B.V.
  • Class Amines; Amphetamines; Anxiolytics; Behavioural disorder therapies; Benzodioxoles; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Post-traumatic stress disorders
  • Phase II Alcoholism

Most Recent Events

  • 01 Oct 2024 Lykos Therapeutics initiates the phase III MDMA-PE trial for Post-traumatic stress disorders in the US (NCT06117306)
  • 09 Aug 2024 Lykos plans to request a meeting with the US FDA to discuss the agency's recommendations for a resubmission seeking regulatory approval for midomafetamine .
  • 09 Aug 2024 Lykos Therapeutics receives complete response letter from the FDA for methylenedioxymetamfetamine in Post-traumatic stress disorders

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top